株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ピーナッツ・アレルギー : パイプライン分析

Peanut Allergy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 251569
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
ピーナッツ・アレルギー : パイプライン分析 Peanut Allergy - Pipeline Review, H1 2017
出版日: 2017年05月09日 ページ情報: 英文 84 Pages
概要

ピーナッツ・アレルギーは特に子どもによく見られます。 ピーナッツへのアレルギー反応は、通常摂取後数分内に起こり、症状は軽度なものから重度のものまで分かれます。 ピーナッツ・アレルギーの兆候および症状は、口および喉周辺にじんましんや赤くなったりむくんだり、かゆかったりヒリヒリしたり、下痢、胃痙攣、吐き気あるいは嘔吐のような消化器官の問題が起きたり、喉が締まったり、息切れあるいは息がぜいぜい音を立てたり、鼻水が出たりします。

当レポートでは、ピーナッツ・アレルギーの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ピーナッツ・アレルギー 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • aldesleukin
  • ピーナッツ・アレルギーのアレルゲン
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • ピーナッツ・アレルギー/喘息向け CYP11A1 阻害薬
  • 呼吸器系・ 免疫疾患向け PIM-1 キナーゼ阻害薬
  • PER-1080
  • pnut-ASIT
  • ピーナッツ・アレルギー向け組み換えタンパク質
  • ピーナッツ・アレルギー 向け組み換えベクターワクチン
  • VTC-064

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9246IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy - Overview
    • Peanut Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies Inc
    • Aimmune Therapeutics Inc
    • Alfacyte Ltd
    • Allergy Therapeutics Plc
    • AnaptysBio Inc
    • ASIT Biotech SA
    • Astellas Pharma Inc
    • BioLingus AG
    • DBV Technologies SA
    • HAL Allergy BV
    • Intrommune Therapeutics
    • Sanofi
  • Peanut Allergy - Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANB-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANN-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HALMPE-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PER-1080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pnut-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyvac Peanut - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-439794 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 2 for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
      • Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
      • Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
      • Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
      • Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
      • Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
      • Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine
      • Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine
      • Dec 20, 2016: Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
      • Dec 13, 2016: AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020
      • Nov 28, 2016: Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
      • Nov 11, 2016: DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting
      • Oct 26, 2016: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology
      • Oct 24, 2016: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
      • Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2017
  • Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2017
  • Peanut Allergy - Pipeline by Alfacyte Ltd, H1 2017
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017
  • Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2017
  • Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2017
  • Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2017
  • Peanut Allergy - Pipeline by BioLingus AG, H1 2017
  • Peanut Allergy - Pipeline by DBV Technologies SA, H1 2017
  • Peanut Allergy - Pipeline by HAL Allergy BV, H1 2017
  • Peanut Allergy - Pipeline by Intrommune Therapeutics, H1 2017
  • Peanut Allergy - Pipeline by Sanofi, H1 2017
  • Peanut Allergy - Dormant Projects, H1 2017
  • Peanut Allergy - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Peanut Allergy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top